The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA-positive colorectal cancer.
 
Kanwal Raghav
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding - Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Taowei Ke
No Relationships to Disclose
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - Arcus Biosciences (Inst); AstraZeneca (Inst); Curio Science (Inst); CytomX Therapeutics (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Pfizer (Inst); Takeda (Inst)
Research Funding - 1200 Pharma (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Fog Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); IMPAC Medical Systems (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Leap Therapeutics (Inst); Neogene (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Seagen (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Takeda (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Lorenzo Antonuzzo
Honoraria - Amgen; AstraZeneca; Novartis; Roche
Consulting or Advisory Role - Merck Serono; MSD Oncology
 
Karen-Lise Spindler
Honoraria - BMS Norway; Boston Scientific; Daiichi Sankyo Europe GmbH; Incyte Biosciences Denmark ApS
Travel, Accommodations, Expenses - Amgen; Merck; Nordic Drugs; Roche
 
Sae-Won Han
Consulting or Advisory Role - Abbvie; AstraZeneca; Natera
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeyondBio (Inst); Boryung (Inst); Cell Biotech (Inst); GC Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); Hengrui Pharmaceutical (Inst); IMBdx (Inst); Janssen (Inst); Jeil Pharmaceutical Co (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck KGaA (Inst); Mirati Therapeutics (Inst); MSD (Inst); Roche (Inst); Seagen (Inst)
 
Kun-Huei Yeh
Honoraria - Amgen; Bristol-Myers Squibb; Daiichi Sankyo; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; TTY Biopharm
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; DSI/AZ; MSD; MSD; Novartis; Ono Pharmaceutical; Pfizer; Pierre Fabre; Takeda
Travel, Accommodations, Expenses - Merck; Ono Pharmaceutical; Pfizer; Takeda
 
Zhe Zhang
Employment - Abbvie; Genentech
Stock and Other Ownership Interests - Abbvie; Genentech
Travel, Accommodations, Expenses - Abbvie; Genentech
 
Martha Neagu Aristide
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Patents, Royalties, Other Intellectual Property - Am on patent applications for IAs I worked on at AbbVie (Inst)
 
Chika Yamagishi
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Henry Chang
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Ou Zhao
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Ramya Seshadri
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Aparna Parikh
Stock and Other Ownership Interests - CADEX Genomics; OneCell Diagnostics India; Parithera; X genomes
Consulting or Advisory Role - 3T BioSciences; Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; CareSet; Caris Life Sciences; Checkmate Pharmaceuticals; CVS; Delcath Systems; DoMore Diagnostics; Exact Sciences; Foundation Medicine; GlaxoSmithKline; Guardant Health; Illumina; Incyte; Lilly; Merck; MPM Capital; Natera; Pfizer; Phesi; Regeneron; SAGA Diagnostics; Seagen; Summit pharmaceuticals; Taiho Oncology; Takeda; Takeda; Third Rock Ventures; UpToDate; Value Analytics Labs; Value Analytics Labs; Xilio Therapeutics; Zola
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Erasca, Inc; Genentech (Inst); Guardant Health (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); PMV Pharma; PureTech (Inst); Syndax
Travel, Accommodations, Expenses - Karkinos Healthcare; Karkinos Healthcare
Other Relationship - C2i genomics; CADEX Genomics; Parithera; Xact Robotics